

Product Data Sheet

Product Name: LY3020371 hydrochloride

Cat. No.: GC36509

Chemical Properties

Cas. No. 1377615-44-5

SMILES O=C([C@@]1(N)[C@]2([H])[C@@H](C(O)=O)[C@]2([H])[C@H](O)[C@H]1CSC3=CC=C(C(F)C(F)=C3)O.[H]Cl


Formula $C_{15}H_{16}ClF_2NO_5S$ M.Wt 395.81

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

LY3020371 hydrochloride is a potent, selective metabotropic glutamate 2/3 receptor (mGlu2/3) antagonist with K_i of 5.3 and 2.5 nM, potently blocks cAMP formation with IC_{50} of 16.2 nM[1]. LY3020371 hydrochloride exerts an antidepressant-like signature in vivo[2]. mGluR2|5.3 nM (K_i)|mGluR3|2.5 nM (K_i)

LY3020371 hydrochloride (LY3020371.HCl) displaces binding of the mGlu2/3 agonist ligand [3H]-459477 with high affinity (hmGlu2 K_i =5.26 nM; hmGlu3 K_i =2.50 nM)[1]. LY3020371 hydrochloride (LY3020371.HCl) (0.1 nM-100 μ M; 1 hours) potently blocks mGlu2/3 agonist (DCG-IV)-inhibited, forskolin-stimulated cAMP formation (IC_{50} =16.2 nM), an effect that was similarly observed in hmGlu3-expressing cells (IC_{50} =6.21 nM)[1]. LY3020371 hydrochloride (LY3020371.HCl) blocks agonist-suppressed spontaneous Ca^{2+} oscillations (IC_{50} =34 nM) and in an intact hippocampal slice preparation (IC_{50} =46 nM)[1].

LY3020371 hydrochloride (LY3020371.HCl) (Intravenous injection; 3-15 mg/kg) in rats leads to cerebrospinal fluid drug levels that are expected to effectively block mGlu2/3 receptors[1]. LY3020371 hydrochloride (LY3020371) (intraperitoneal injection; 3 mg/kg, 10mg/kg; 2 hours) has clear wake promoting effects, resulting in a large reduction in NREM sleep in the Wistar rats during the light phase[3].

[1]. Witkin JM, et al. In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu2/3 receptor antagonist. *Neuropharmacology*. 2017 Mar 15;115:100-114.

[2]. Witkin JM, et al. Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects. *Pharmacol Biochem Behav*. 2017 Apr;155:43-55. [3]. Wood CM, et al.

Investigating the role of mGluR2 versus mGluR3 in antipsychotic-like effects, sleep-wake architecture and network oscillatory activity using novel Han Wistar rats lacking mGluR2 expression. *Neuropharmacology*. 2018 Sep 15;140:246-259.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA